Amundi Pioneer Asset Management Inc. Acquires 26,339 Shares of FibroGen Inc (FGEN)

Amundi Pioneer Asset Management Inc. raised its holdings in shares of FibroGen Inc (NASDAQ:FGEN) by 11.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 257,096 shares of the biopharmaceutical company’s stock after buying an additional 26,339 shares during the period. Amundi Pioneer Asset Management Inc. owned about 0.30% of FibroGen worth $11,898,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in FGEN. Meeder Asset Management Inc. boosted its position in shares of FibroGen by 622.4% in the fourth quarter. Meeder Asset Management Inc. now owns 614 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 529 shares during the period. Intercontinental Wealth Advisors LLC bought a new position in shares of FibroGen during the fourth quarter worth $37,000. Flinton Capital Management LLC bought a new position in shares of FibroGen during the fourth quarter worth $44,000. Neuburgh Advisers LLC bought a new position in shares of FibroGen during the fourth quarter worth $53,000. Finally, Bank of Montreal Can boosted its position in shares of FibroGen by 177.3% during the fourth quarter. Bank of Montreal Can now owns 1,722 shares of the biopharmaceutical company’s stock worth $80,000 after acquiring an additional 1,101 shares during the last quarter. 66.58% of the stock is owned by institutional investors and hedge funds.

FGEN stock traded up $1.07 during trading on Friday, hitting $47.21. The company had a trading volume of 1,092,031 shares, compared to its average volume of 760,364. The company has a market capitalization of $4.04 billion, a PE ratio of -45.83 and a beta of 1.72. FibroGen Inc has a 52-week low of $37.27 and a 52-week high of $68.55. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.75 and a quick ratio of 7.75.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Wednesday, February 27th. The biopharmaceutical company reported $0.23 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.40. The company had revenue of $108.05 million for the quarter, compared to the consensus estimate of $72.15 million. FibroGen had a negative net margin of 40.58% and a negative return on equity of 16.84%. The firm’s revenue was up 251.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.27) EPS. Sell-side analysts forecast that FibroGen Inc will post -0.97 EPS for the current fiscal year.

In related news, CEO Thomas B. Neff sold 18,400 shares of the firm’s stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $46.81, for a total value of $861,304.00. Following the transaction, the chief executive officer now owns 2,550,176 shares of the company’s stock, valued at approximately $119,373,738.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Kalevi Kurkijarvi sold 4,000 shares of the stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $48.09, for a total transaction of $192,360.00. Following the transaction, the director now owns 27,700 shares in the company, valued at $1,332,093. The disclosure for this sale can be found here. Insiders sold a total of 328,721 shares of company stock worth $17,983,268 in the last ninety days. 8.96% of the stock is currently owned by insiders.

A number of equities analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of FibroGen from a “hold” rating to a “buy” rating and set a $52.00 target price for the company in a research report on Tuesday, January 8th. BidaskClub raised shares of FibroGen from a “hold” rating to a “buy” rating in a research note on Saturday, December 22nd. Piper Jaffray Companies began coverage on shares of FibroGen in a research note on Friday, April 12th. They set a “neutral” rating and a $65.00 price target on the stock. TheStreet raised shares of FibroGen from a “d+” rating to a “c-” rating in a research note on Friday, March 29th. Finally, ValuEngine downgraded shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 14th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. FibroGen has an average rating of “Buy” and an average price target of $71.17.

COPYRIGHT VIOLATION WARNING: This report was reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/amundi-pioneer-asset-management-inc-increases-position-in-fibrogen-inc-fgen.html.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Read More: Why do commodities matter?

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.